Recent studies have suggested a possible correlation between obesity and adenovirus 36 (Adv36) infection in humans. As information on adenoviral DNA presence in human adipose tissue are limited, we evaluated the presence of Adv36 DNA in adipose tissue of 21 adult overweight or obese patients. Total DNA was extracted from adipose tissue biopsies. Virus detection was performed using PCR protocols with primers against specific Adv36 fiber protein and the viral oncogenic E4orf1 protein nucleotide sequences. Sequences were aligned with the NCBI database and phylogenetic analyses were carried out with MEGA6 software. Adv36 DNA was found in four samples (19%). This study indicates that some individuals carry Adv36 in the visceral adipose tissue. Further studies are needed to determine the specific effect of Adv36 infection on adipocytes, the prevalence of Adv36 infection and its relationship with obesity in the perspective of developing a vaccine that could potentially prevent or mitigate infection.
INTRODUCTION
Prevalence of obesity is increasing in recent decades both in developed and developing countries, without a definite explanation: apart from nutritional and sedentary life behaviors, also environmental factor(s) should be considered. A convincing explanation for this phenomenon is lacking, although it is well recognized that obesity is the result of gene-environment interactions. The obesity prevalence increased in all age groups, including children. [1] [2] [3] [4] The interaction between genetics, metabolic, social, cultural and environmental factors, including viral infection, addresses many different cofactors for the development of obesity. The role of bacteria and viruses as potential etiological agents has been suggested, and the term 'infectobesity' has been proposed. 5 Adv36 infection increases adiposity in animals 6, 7 and reduces significantly the concentrations of cholesterol and triglycerides compared with uninfected controls. 4 Interestingly, longitudinal studies in monkeys showed a 15-30% increase of body weight, a 66% increase in body fat, and a reduction of serum cholesterol after natural infection with Adv36. 7 These putative causal effects of Adv36 infection in animals are mirrored in humans who have greater body weight and body fat, but relative hypolipidemia, greater potential of preadipocyte differentiation, better glycemic control and lower inflammatory response of adipose tissue in infected compared with uninfected individuals. 4, 8 Experimental studies involving chickens, mice, rhesus monkeys, marmoset monkeys and hamsters have shown that infection of Adv36 may lead to greater spontaneous differentiation of preadipocytes into mature fat cells, reduced leptin secretion and increased secretion of glycerol dehydrogenase-6-phosphate. In the first study on nonhuman primates it was observed spontaneously occurring Adv36 antibodies in male rhesus monkeys and an association of positive antibody status with weight gain and decreased plasma cholesterol. 9 In humans, the natural infection with Adv36 has been defined by seropositivity 4, 9 and only a few studies demonstrated the presence of the viral DNA in adipose tissue. 10, 11 The first study on the prevalence of AdV36 antibodies in adult humans in the United States showed that about 30% of obese and 11% of non-obese had been infected, suggesting a correlation of obesity with the infection. 4 The prevalence of Adv36 infection in obese adults ranged from 65% in Italy to 6% in Belgium/ Netherlands; the prevalence in obese and non-obese children was 28% and 18%, respectively. 9 In this study, we challenged the detection of Adv36 in human adipose tissue samples by determining the presence of Adv36 DNA.
MATERIALS AND METHODS

Patients
Twenty-one patients (Body Mass Index, BMI 25-54 (34.2 ± 10.7) kg m − 2 ) (8 males, 13 females), 23-65 year (47.8 ± 14.6), were enrolled into the study. The patients underwent complete medical examination, anthropometric measurements (body weight, height and waist circumference), determination of fasting plasma glucose and insulin, HbA1c, total cholesterol, high density lipoproteincholesterol, low density lipoprotein-cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, erythtrocyte sedimentation rate and C-reactive protein ( Table 1) . Patients with acute disease, diabetes, cancer, chronic liver and renal disease, serological positive tests for hepatitis B and C, were excluded. The study was approved by the ethical committee of the Sapienza University of Rome, Policlinico Umberto I, and was concordant with Helsinki Declaration. Each patient gave a written informed consent before admission to the study.
Detection of Adv36 DNA Adipose tissue (30 mg) from obese (BMI ⩾ 30 kg m − 2 ) and overweight (BMI o 30 kg m − 2 ) patients were collected by the surgeon during surgical procedures. Total DNA was extracted from the adipose tissue using DNeasy Tissue Mini Kit following the manufacturer's instructions (Qiagen, Hilden, Germany). Extracted DNA was used immediately for PCR using PCR Master Mix (Qiagen) and degenerate primer sets targeting the fiber protein gene. External primer forward were used for first PCR, 477-bp DNA fragment obtained, 12 and for the semi-nested PCR step inner forward primer was used 5′-AGTTGAAACAGCAAGAGACTCAAAG-3′, yielding a final product of 302 bp. Briefly, 0.4 mM of primers and 2 μl of extracted DNA were used in PCR in a final volume of 20 μl. PCR were performed under the following conditions: denaturation at 94°C for 2 min, and 40 cycles at 94°C for 45 s, 60°C for 1 min, and 72°C for 1 min, followed by a final elongation step of 72°C for 7 min. For the second round semi-nested PCR, the inner oligos (0.4 mM) were used, with 2 μl of DNA template obtained from the first PCR using Master Mix (Qiagen).
To obtain a different viral DNA fragment for sequencing, positive samples to the first protocol described above, were also analyzed using a second PCR procedure with primer pairs E4orf1 amplifying a 320 bp region in ORF1. 12 The amount of DNA and the parameters for the second PCR protocol was similar to the first one. For the exclusion of the PCR inhibitors, all samples were tested in a separate run using β-actin primers (Figure 1c ). 13 All samples resulting negative were re-tested in nested-PCR using a 10-fold dilution of the first PCR to evaluate if negative results were due to inhibition. The amplification products were visualized on 1.5% agarose gel electrophoresis under ultraviolet-light. Negative PCR controls were water and DNA from uninfected patients. Positive control was DNA from Human Adv36 (ATCC: VR-913) infected A549 cells (American Type culture Collection ATCC, Rockville, MD, USA). To avoid cross-contaminations each phase of diagnostic routine (from sample preparation throughout PCR) was completed in separate rooms. Negative controls (DEPC-water samples) were included during DNA extraction and PCR. The samples double checked independently in different days for four times.
Sequencing
Positive DNA amplicons were purified by gel extraction kit Nucleospin (Macherey-Nagel, Duren, Germany) and sequencing reactions were carried out by Biofab (Biofab srl, Rome, Italy). Sequences from this study were deposited in GenBank (accession nos. KP861237-861240). Nucleotide sequences were analyzed using the DNASIS Max software (Hitachisoft, Hitachi Software Engineering Company, Alameda, CA, USA), and were compared with Adv sequences available in the NCBI GenBank (http://www. ncbi.nlm.nih.gov). The neighbor-joining tree was drawn by MEGA6 software (http://www.megasoftware.net), using Kimura-2 as correction factor. 14 Figure 1 (a and b) shows the four Adv36-positive fat tissue biopsies evaluated by conventional PCRs. Two positive patients were obese (BMI 44 kg m − 2 and 41 kg m − 2 ) and two overweight (BMI 26 kg m − 2 and 28 kg m − 2 ). Partial nucleotide sequenced performed on four fiber protein fragments confirmed the presence of Adv36 (Figure 1c  and d) . Successful sequencing to obtain long sequences to draw the neighbor-joining was possible for only three samples, due to the short sequence of the fourth sample. Sequencing and comparative analysis revealed almost a 100% nucleotide identity. The sequences were deposited on NCBI GenBank (Acc. KP861237-861239).
RESULTS
A second nested PCR protocol, that amplifies a 320 nt E4orf1 gene, was performed on the positive samples to evaluate a different Adv36 gene product. The positivity was confirmed by both tests in one out of the four samples. The E4orf1 fragment was sequenced (NCBI GenBank: Acc. KP861240) and the alignment of the sequence in the overlapping regions (267 nt) showed a 100% nucleotide identity. A phylogenetic tree was drawn using E4orf1 fragment (Figure 1b) . The alignment confirmed a strict correlation between the Adv36 genomes detected in fat tissue with Adv36 strains reported in NCBI with highest nucleotide identity with previously submitted Adv36 strain. No mutations in the E4orf1 gene (Adv36) were found. The Adv36-positive patients had normal levels of fasting plasma glucose and insulin, aspartate aminotransferase, alanine aminotransferase, high density lipoprotein-C, cholesterol and triglycerides.
DISCUSSION
The association of natural Adv36 infection with obesity has been described both in adults and in children. 9 In an Italian population of patients, a significant higher prevalence of Adv36 in obese adults compared with non obese (65 vs 33%) has been reported. 15 In Adv36 infected patients, BMI and waist-to-hip ratio, a marker for abdominal obesity, were significantly higher compared with negative controls, suggesting a possible association between Adv36 and obesity.
Several studies reported a high prevalence of neutralizing antibodies to Adv36, as detected by serum neutralization assay and enzyme linked immunosorbent assay, in obese individuals, but detection of Adv36 DNA in human fat tissue is still a key component for the evidence or association. However, there is a mismatch between the high seroprevalence of Adv36 in obesity, which is fairly well documented, and detection of the virus in clinical samples. 16 Although this finding might be explained by the persistence of antibodies after recovery from the viral infection, this discrepancy needs further investigation. 16 In this paper, we report our results on the Adv36 DNA detection in visceral human adipose tissue in italian patients. There is limited information on the Adv36 presence in adipose tissue, probably due to the difficulty of virus detection for low viral concentration. The Adv36 genome was detected in both obese and overweight patients. The limited number of samples does not allow a correlation between body weights and virus DNA detection. No significant difference in fasting plasma glucose, triglyceride and cholesterol levels was found in our patients. No relationship was detected between Adv36-positive samples and the inflammation markers, although a positive patient, showed higher C-reactive protein marker concentration. Two different genes of the Adv36 genome (fiber protein and E4orf1 genes), with a nucleotide identity of 100%, were found in one clinical sample demonstrating the high stability of Adv36 genome. 17 The lack of E4orf1 detection Detection of Adenovirus 36 in adult obese patients in three out of the four Adv36 fiber protein-positive samples is intriguing. The low concentration of the Adv36 gene in the adipose tissue and the even lower expression of the E4orf1 gene could explain these findings. 18 The detection rate of Adv36 infection defined by PCR was similar to that reported in adults in the United States. 19 The detection of Adv36 in adipose tissue still remains a challenge, and this study provides a contribution for further research to determine whether Adv36 has an active role in adipose tissue deposits in obese and overweight subjects. The reported uncommon Adv36 infection in type 2 diabetes led us to exclude these patients from our group, however, studies on overweight/ obese individuals with diabetes are warranted. 20 In conclusion, unequivocal confirmation of the role of Adv36 in the development of human obesity could be useful for a better management of the disease. The increasing incidence of pathogen-induced obesity opens new perspectives to the development of vaccines to prevent or cure selected obese individuals. Further research on viruses that contribute to obesity would be helpful. 
